The New Myth
暂无分享,去创建一个
[1] W. Brouwer,et al. Reconciliation of economic concerns and health policy , 2012, PharmacoEconomics.
[2] H. Gravelle,et al. Discounting in economic evaluations: stepping forward towards optimal decision rules. , 2007, Health economics.
[3] A. Gafni,et al. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. , 2006, Social science & medicine.
[4] Jeff Richardson,et al. Can we estimate the 'social' value of a QALY? Four core issues to resolve. , 2005, Health Policy.
[5] M. Drummond,et al. Inclusion of cost effectiveness in licensing requirements of new drugs : The fourth hurdle , 2017 .
[6] Alan Williams,et al. What Could be Nicer than NICE , 2004 .
[7] Michael E. Chernew,et al. Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.
[8] R. Cookson,et al. Equity in health , 2000 .
[9] J. Quiggin,et al. Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? , 1999, Journal of health economics.
[10] A. Williams,et al. Intergenerational equity: an exploration of the 'fair innings' argument. , 1997, Health economics.
[11] John E. Roemer,et al. Interpersonal Comparisons of Well-Being , 1991 .
[12] Peter J. Hammond,et al. Interpersonal Comparisons of Well-being: Interpersonal comparisons of utility: Why and how they are and should be made , 1990 .